Latest Product Launch News

Hydralyte North America reported a 16% rise in Q1 FY25 net sales and improved gross margins, supported by a strategic capital raise and upcoming product launches targeting brain and gut health.

Merino & Co reported a transformative quarter marked by operational upgrades, new product launches, and the integration of cryptocurrency payments, ending with a robust cash position to fuel future growth.

Elixinol Wellness reported a 13.7% year-on-year revenue increase in Q1 FY25, despite a softer quarter compared to record Q4, with ecommerce momentum and strategic initiatives setting the stage for margin recovery and growth in H2.

Acrux Limited reports strong momentum from recent topical pharmaceutical launches, driving a significant uptick in profit share income expected in the coming quarter. The company also secured nearly $4 million through a placement and share purchase plan, alongside a $1.73 million R&D-backed loan.

Atomos Limited reported a $2.3 million operating cash outflow in Q3 FY25 amid seasonal softness and tariff challenges, while announcing a leadership change and a bold expansion into new product categories beyond its core monitor-recorder business.

Tissue Repair Limited reports progress in its Phase 3 clinical trials for TR987® despite enrollment delays caused by US regulatory disruptions, while TR Pro+® sales hit record highs and manufacturing scale-up advances.

Adherium Limited reports a surge in US commercial patients for its Hailie Smartinhaler platform, alongside strategic hires and a new product launch compatible with AstraZeneca inhalers, underpinning plans for a capital raise.

PEXA has achieved a crucial regulatory milestone with FCA approval to operate as an Authorised Payment Institution in the UK, paving the way for its Sale & Purchase product launch later this year.

Optiscan Imaging Ltd has revealed its next-generation InForm™ pathology imaging device and strengthened its executive team, while reporting a robust cash position supported by a $1.775 million R&D tax refund for the quarter ended 31 March 2025.

Control Bionics reports its strongest US revenue in years alongside Australia’s best quarter since 2022, propelled by new product launches and strategic investments.

Universal Biosensors reported a 28% increase in customer receipts to $1.6 million for Q1 2025, alongside improved cash flow and plans for a new product launch later this year.

Decidr AI Industries signals a strategic pivot to AI with a successful $11 million capital raise, new multi-year contracts, and expanded global partnerships, driving early commercial traction and robust e-commerce growth.